News & Events about Arvinas Inc.
Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population NEW HAVEN, Conn., May 05, 2023 (GLOBE ...
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform...
Arvinas, Inc. (NASDAQ:ARVN Get Rating) has been given a consensus rating of Moderate Buy by the eighteen brokerages that are covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The...
Oerth's unique PROTAC® protein degradation technology is expected to be a new, game-changing generation of more sustainable crop protection products / The agreement recommits to the combination of Oerth Bio's specialized expertise designing PROTAC® degraders for agriculture with...
Arvinas, Inc. (NASDAQ:ARVN Get Rating) Equities researchers at HC Wainwright issued their Q2 2023 earnings estimates for Arvinas in a research report issued to clients and investors on Friday, February 24th. HC Wainwright analyst A. Fein forecasts that the company will post earnings ...